PT  - JOURNAL ARTICLE
AU  - Barnes, K.
AU  - Colagiuri, B.
TI  - Positive attribute framing increases COVID-19 booster vaccine intention for unfamiliar vaccines
AID  - 10.1101/2022.01.25.22269855
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.25.22269855
4099  - http://medrxiv.org/content/early/2022/01/28/2022.01.25.22269855.short
4100  - http://medrxiv.org/content/early/2022/01/28/2022.01.25.22269855.full
AB  - Positive framing has been proposed as a potential intervention to increase COVID-19 vaccination intentions. However, most available research has examined fictitious or unfamiliar treatments. This pre-registered study compared positively and negatively attribute-framed side effect information for real COVID-19 booster vaccines (AstraZeneca, Pfizer, Moderna) and measured intentions pre- and post-intervention in 1,222 UK-based participants. Positive framing increased booster intentions among those with low baseline intentions overall. As hypothesized, however, vaccine familiarity significantly modulated this effect, with positive framing being effective for the least familiar vaccine (i.e., Moderna), while standard negative framing appeared to increase intentions for familiar vaccines (AstraZeneca/Pfizer). These findings provide important new evidence that positive framing could improve vaccine uptake globally when switches or new developments require individuals to receive less familiar vaccines – as is currently the case for millions of booster vaccines across the world. Positive framing of familiar vaccines, however, should be treated with caution.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://aspredicted.org/53ph4.pdf Funding StatementThis research was supported by Australian Research Council grants DP180102061 and DP200101748. The funding body had no involvement in study design, analysis, interpretation, writing, or the decision to submit the present article for publicationAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of Sydney Human Research Ethics Committee of the University of Sydney gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online through the Open Science Framework repository https://osf.io/d5cvn/?view_only=cb90eca9ddf446c8901652ab0344fa05